Trial Profile

A pivotal study assessing PD-0325901 in patients with neurofibromatosis type 1 with plexiform neurofibromas

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 08 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mirdametinib (Primary)
Indications Neurofibromatosis 1
Focus Registrational; Therapeutic Use
Sponsors SpringWorks Therapeutics

Most Recent Events

01 Apr 2019 According to a SpringWorks Therapeutics media release, the company announced that this pivotal study will initiate in the first half of 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com